Meeting
2014 Gastrointestinal Cancers Symposium
Cost differential among systemic therapies for colon cancer.
Authors
Hasan Nadeem
Medical College of Wisconsin, Milwaukee, WI
Hasan Nadeem , Thejus T. Jayakrishnan , T. Clark Gamblin , Kiran Turaga
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 583)
DOI
10.1200/jco.2014.32.3_suppl.583
Abstract #
583
Poster Bd #
D32
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Chemotherapy for metastatic colon cancer: Effect on survival when the dose is reduced due to side effects.
First Author: Stefan Munker
Poster
2016 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).
First Author: Kei Muro
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results.
First Author: Patricio Eduardo Yanez
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer.
First Author: Riya Jayesh Patel